---
search:
  boost: 2 
---

# Uterine Fibroids

This is a subcategory of Endocrine Agents.

## Formulary

### Preferred

| Preferred                                | Generic Name                                                                |         Quantity          |        Time (Days)        |
| :--------------------------------------- | :-------------------------------------------------------------------------- | :-----------------------: | :-----------------------: |
| Lupron Depot <sup>PA</sup> 3.75, 11.25mg | Leuprolide Acetate for Depot IM Susp 3.75 MG & 11.25 MG                     | Determined pursuant to PA | Determined pursuant to PA |
| Oriahnn <sup>PA QL</sup>                 | Elagolix / Estradiol / Norethindrone Acetate & Elagolix Cap (all strengths) | Determined pursuant to PA | Determined pursuant to PA |
| Myfembree <sup>PA QL</sup>               | Relugolix / Estradiol / Norethindrone Acetate Tab (all strengths)           | Determined pursuant to PA | Determined pursuant to PA |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
|               |              |          |             |

## Authorizations

**Length of Authorizations**: Up to 180 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **90 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Additional Information

- A total lifetime duration of therapy of 730 days between Oriahnn and Myfembree or 180 days for Lupron Depot will be authorized

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=61)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=22)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
